OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA

Bernadette Dian Novita, MD.,PhD87 enrolled

Overview

In order to compare the effectiveness between Remdesivir and Favipiravir, an observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021

Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2). Antiviral therapies are considered to be one of the COVID-19 treatments. Remdesivir and favipiravir are the antivirals recommended by Indonesia's 3rd COVID-19 Management Guidelines. They have a similar mechanism to inhibit virus replication, specifically by inhibiting RNA-dependent RNA polymerase (RdRp) of the virus. Several studies reported that patients who received these antivirals had a lower duration of hospitalization. However, the effectiveness comparison of remdesivir and favipiravir remains unknown. An observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021 are collected by consecutive sampling technique, and this research was carried out at Gotong Royong Hospital Surabaya.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Duration of Hospitalization Clinical Manifestation of COVID-19

Interventions

RemdesivirDRUG

The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 97 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (eighteen years old or above) with moderate to severe COVID-19 (categorized based on KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK. 01. 07/MENKES/413/2020); * Admitted to Gotong Royong Hospital Surabaya from January 2021 to August 2021; * Received remdesivir OR favipiravir with minimal five days of treatment * Not in pregnancy and lactating condition Exclusion Criteria: * female patient with pregnancy and lactation * patient whom was passed away or forced home during two-weeks observation period

Locations (1)

Gotong Royong Surabaya Hospital

Surabaya, East Java, Indonesia

Outcomes

Primary Outcomes

Clinical manifestation

Oxygen needs, cough, dyspnea

Time frame: 2 weeks since drug (remdesivir OR favipiravir) administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.